BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mydicar: Final Phase I/II data

Final data from the double-blind Phase II portion of the U.S. Phase I/II CUPID trial in 39 patients showed that high-dose Mydicar significantly reduced cardiovascular events defined by death, the need for left ventricular assist device or cardiac transplant, worsening of heart failure or heart failure-related hospitalizations vs. placebo (p=0.04). Mean duration of hospitalization was also reduced in the high-dose Mydicar group vs. placebo during the 6-month treatment period (0.2 vs. 2.1 days/patient). Quality of life as measured by the Minnesota Living...

Read the full 389 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >